©2024 Humana Healthcare Research
By: Insiya B. Poonawalla, Yihua Xu, Rainelle Gaddy, Alex James, Matt Ruble, Salina Burns, Suzanne W. Dixon, Brandon T. Suehs
This retrospective cohort study using real-world claims to describe the demographics and clinical characteristics of a large population of Medicare Advantage prescription drug (MAPD) confirmed the association between anticholinergic (ACH) medication exposure and increased risk of dementia/Alzheimer’s disease diagnosis and mortality. Reducing ACH exposure may potentially minimize long-term adverse effects in older adults. Results suggest populations which may benefit from targeted interventions to reduce ACH polypharmacy.